“The Hanson Wade team provides a solid platform for communicating exciting new breakthroughs in cell therapy for hard-to-treat autoimmune syndromes”

– Marko Radic, Associate Professor, Department of Microbiology, Immunology & Biochemistry, University of Tennesse Health Science Center 

“The adaptation of cell-based therapies to treat refractory autoimmune diseases will reshape the way we think about broader applications for other diseases. This summit will stimulate those conversations as we look to the future.”

-  Phil Johnson, Chief Executive Officer, Interius Biotherapeutics